Status:
COMPLETED
The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle
Lead Sponsor:
East Tennessee State University
Collaborating Sponsors:
Takeda Pharmaceuticals North America, Inc.
Conditions:
Diabetes Type 2
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
Subjects with type 2 diabetes will be treated with Actos or placebo for eight weeks and needle biopsies of muscle will quantify changes in any of seven different glucose transport proteins in muscle.
Detailed Description
Twelve subjects with type 2 diabetes, with fair control on oral medication, will be recruited to participate in a randomized, double-blind, placebo-controlled study of the impact on muscle glucose tra...
Eligibility Criteria
Inclusion
- diabetes, type 2
- HbA1c less than 8.5
Exclusion
- insulin therapy
- renal insufficiency
- clinically apparent coronary disease
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01799850
Start Date
March 1 2002
End Date
March 1 2004
Last Update
February 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ETSU Quillen College of Medicine
Johnson City, Tennessee, United States, 37614